海正藥業(600267.SH)快速拉昇 與聖兆藥物擴大原料藥合作
格隆匯4月24日丨海正藥業(600267.SH)午後出現直線拉昇走勢,目前漲5.05%報17.69元,暫成交12.3億元,最新總市值172億元。聖兆藥物21日發公告稱,與海正藥業簽署重大合同,聖兆藥物委託海正藥業開發阿立哌唑(一水合物)無菌原料藥的生產工藝,雙方在聖兆藥物指定的原料藥受託生產企業共同完成阿立哌唑(一水合物)無菌原料藥工藝驗證批的生產。這是聖兆藥物與海正藥業達成的第2個原料藥合作,均為精神神經領域產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.